About
Zietchick Research Institute is the first and only life science
start-up that develops new therapeutics specifically for the eye health of
children and women.
The organization places its focus on the common eye disease called
proliferative retinopathy, which is among the leading causes of blindness in
the United States. The disease affects both males and females, although
research conducted by Zietchick showed women who have the disease have an
excess of hormones in their eyes. By targeting these hormones, Zietchick believes
that the disease can be treated. .
The organization is developing the first eyedrops that address the
unique pathophysiology of the female eye disease, which can be used in both
adulthood and infancy. Furthermore, the treatment is being designed to treat
the back of the eye, where the damage of retinopathy is pronounced.
Aside from this, Zietchick is also developing the first hormonal
eyedrop for premature infants. When babies are born prior to their full-term,
they may be deprived of hormones from the placenta that are critical in their
development. By using Zietchick’s eyedrops , the eyes of premature babies will
continue to develop normally even outside of the womb. This may also prevents
retinopathy of prematurity from occurring.
Zietchick Research Institute hopes to prevent retinopathy for everyone
through these revolutionary treatments.
Comments
Post a Comment